Additional payment received to exercise option to expand number of targets.

No definition available.

Name:	nrix_AdditionalPaymentReceivedToExerciseOptionToExpandNumberOfTargets
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Additional Payments

+ References

No definition available.

+ Details

Name:	nrix_AdditionalPayments
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaboration agreement contract term.

+ References

No definition available.

+ Details

Name:	nrix_CollaborationAgreementContractTerm
Namespace Prefix:	nrix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaboration Agreement Contract Term, Extension

+ References

No definition available.

+ Details

Name:	nrix_CollaborationAgreementContractTermExtension
Namespace Prefix:	nrix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaboration Agreement Expiration Term

+ References

No definition available.

+ Details

Name:	nrix_CollaborationAgreementExpirationTerm
Namespace Prefix:	nrix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Contractual extended research period.

+ References

No definition available.

+ Details

Name:	nrix_ContractualExtendedResearchPeriod
Namespace Prefix:	nrix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Contractual initial research period.

+ References

No definition available.

+ Details

Name:	nrix_ContractualInitialResearchPeriod
Namespace Prefix:	nrix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Additional Specified Drug Targets

+ References

No definition available.

+ Details

Name:	nrix_NumberOfAdditionalSpecifiedDrugTargets
Namespace Prefix:	nrix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Drug Candidates

+ References

No definition available.

+ Details

Name:	nrix_NumberOfDrugCandidates
Namespace Prefix:	nrix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Performance Obligations

+ References

No definition available.

+ Details

Name:	nrix_NumberOfPerformanceObligations
Namespace Prefix:	nrix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Products Arising From Collaboration

+ References

No definition available.

+ Details

Name:	nrix_NumberOfProductsArisingFromCollaboration
Namespace Prefix:	nrix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Specified Drug Targets

+ References

No definition available.

+ Details

Name:	nrix_NumberOfSpecifiedDrugTargets
Namespace Prefix:	nrix_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Proceeds from Collaboration Agreement, Extension Payment

+ References

No definition available.

+ Details

Name:	nrix_ProceedsFromCollaborationAgreementExtensionPayment
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Research milestones payments received.

+ References

No definition available.

+ Details

Name:	nrix_ResearchMilestonesPaymentsReceived
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue, Remaining Performance Obligation, Variable Consideration Amount, Certain Sales Milestones

+ References

No definition available.

+ Details

Name:	nrix_RevenueRemainingPerformanceObligationVariableConsiderationAmountCertainSalesMilestones
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue, Remaining Performance Obligation, Variable Consideration Amount, Regulatory Milestones

+ References

No definition available.

+ Details

Name:	nrix_RevenueRemainingPerformanceObligationVariableConsiderationAmountRegulatoryMilestones
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue, Remaining Performance Obligation, Variable Consideration Amount, Research And Development Milestones

+ References

No definition available.

+ Details

Name:	nrix_RevenueRemainingPerformanceObligationVariableConsiderationAmountResearchAndDevelopmentMilestones
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue, Remaining Performance Obligation, Variable Consideration Amount, Target Licensing And Reservation

+ References

No definition available.

+ Details

Name:	nrix_RevenueRemainingPerformanceObligationVariableConsiderationAmountTargetLicensingAndReservation
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Upfront payment.

+ References

No definition available.

+ Details

Name:	nrix_UpfrontPayment
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Upfront payment of additional fees.

+ References

No definition available.

+ Details

Name:	nrix_UpfrontPaymentOfAdditionalFees
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Variable consideration included in transaction price.

+ References

No definition available.

+ Details

Name:	nrix_VariableConsiderationIncludedInTransactionPrice
Namespace Prefix:	nrix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerAssetNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

+ References

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12A

+ Details

Name:	us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=nrix_GileadAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nrix_SanofiAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nrix_PfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=nrix_LicenseRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nrix_GileadAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nrix_SanofiAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nrix_PfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreements (Details) $ in Thousands	1 Months Ended							2 Months Ended	3 Months Ended			9 Months Ended
Collaboration Agreements (Details) $ in Thousands	Mar. 31, 2024	Sep. 30, 2023 USD ($) product	Apr. 30, 2023 USD ($)	Jul. 31, 2022	Jan. 31, 2021 USD ($) performanceObligation target	Dec. 31, 2019 USD ($) target	Jun. 30, 2019 USD ($) candidate target	Mar. 31, 2024	Aug. 31, 2024 USD ($)	May 31, 2024 USD ($)	Aug. 31, 2023 USD ($)	Aug. 31, 2024 USD ($)	Aug. 31, 2023 USD ($)	Nov. 30, 2023 USD ($)	Mar. 31, 2023 target
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of drug candidates \| candidate							1
Revenue									$ 12,588		$ 18,467	$ 41,265	$ 61,828
Deferred revenue, current									47,997			47,997		$ 48,098
Gilead Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development milestone payments									513,500			513,500
Target licensing and reservation payments									60,000			60,000
Certain sales milestones payments									1,200,000			1,200,000
Sanofi Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development milestone payments									389,000			389,000
Target licensing and reservation payments									61,800			61,800
Certain sales milestones payments									1,000,000			1,000,000
Regulatory milestone payments									500,000			500,000
Pfizer
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development milestone payments									631,000			631,000
Target licensing and reservation payments									19,500			19,500
Certain sales milestones payments									1,800,000			1,800,000
Regulatory milestone payments									873,000			873,000
License revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue									0		0	$ 0	20,000
Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of drug candidates \| candidate							2
Gilead Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Drug targets \| target							5								1
Collaboration agreement contract term							5 years					5 years
Term extension								2 years
Extension payment										$ 15,000
Revenue									500		11,600	$ 10,000	24,700
Upfront payment							$ 45,000
Upfront payment of additional fees							$ 3,000
Research milestones payments received												47,000
Expiration term							10 years
Variable consideration included in transaction price												47,000
Collaboration revenue recognized from opening contract liability									1,900		6,600	1,900	15,100
Performance obligation satisfied											4,700		8,000
Recorded deferred revenue									13,100			13,100
Deferred revenue, current									9,200			9,200		10,000
Gilead Agreement \| License revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue			$ 20,000								20,000		20,000
Gilead Agreement \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional payments									1,800,000			1,800,000
Sanofi Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Drug targets \| target					5	3
Term extension	2 years
Revenue									5,900		6,800	16,200	17,100
Upfront payment						$ 55,000
Research milestones payments received												13,000
Expiration term						10 years
Variable consideration included in transaction price					$ 13,000
Collaboration revenue recognized from opening contract liability									5,900		5,600	14,700	15,400
Performance obligation satisfied									0		$ 1,100	1,200	$ 1,100
Recorded deferred revenue														24,900
Deferred revenue, current									14,600			$ 14,600		20,300
Additional payment received to exercise option to expand number of targets					$ 22,000
Additional drug targets \| target					2
Number of performance obligations \| performanceObligation					1
Contractual initial research period												4 years 3 months
Contract assets														4,000
Sanofi Agreement \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional payments									2,000,000			$ 2,000,000
Extended research term				5 years 3 months
Sanofi Agreement \| Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Extended research term				1 year
Pfizer
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue									4,200			13,100
Upfront payment		$ 60,000
Research milestones payments received												5,000
Additional payments									3,400,000			3,400,000
Variable consideration included in transaction price		$ 5,000
Collaboration revenue recognized from opening contract liability									4,200			12,300
Performance obligation satisfied									0			100
Recorded deferred revenue									50,200			50,200		58,300
Deferred revenue, current									$ 24,200			$ 24,200		$ 17,900
Contractual initial research period		4 years
Products arising from collaboration \| product		2